Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to results that did not meet expectations.
The company presented data on 23 January at the American Society of Clinical Oncology Oncology’s Gastrointestinal Cancers Symposium from the Phase II ASPEN-06 trial of the CD47-targeting drug evorpacept plus the combination of trastuzumab (Roche’s Herceptin and biosimilars), ramucirumab (Eli Lilly’s Cyramza) and paclitaxel (TRP), versus
Key Takeaways
- ALX presented data from the Phase II ASPEN-06 study of evorpacept in gastric and GEJ cancer at the ASCO-GI conference, showing improvements in PFS among HER2-positive subpopulations.
- The company plans to provide updates on next steps for the program in the second quarter after meeting with the FDA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?